UNSPSC 51292203: Irolapride

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JS492IR8Z6. European Medicines Agency schedules Irolapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08297MIG. Irolapride generally arises in the molecular formula C19H28N2O3.

UNSPSC 51292203 Irolapride, a Commodity code, does not align with the actual state and local procurement activity tagged under it. The three recent opportunities posted under this code solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are irolapride or opioid antagonists matching the code's nominal scope. The mismatch suggests either a cataloging error in the source data or a broader tagging issue within the jurisdiction systems issuing these opportunities.

The issuing bodies represent the mix typical of state and local pharmaceutical procurement: a county health department (Seminole County, Florida), a state health agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The recent opportunities show movement toward pharmaceutical supply across county health systems, state Medicaid and employee benefit programs, and cooperative purchasing networks spanning multiple states. A representative solicitation is MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, seeking manufacturers to supply through three authorized wholesalers with awards effective July 1, 2026; Seminole County's IFB for naloxone and safe drug deactivation systems, due July 26, 2023, procuring 1,900 units of naloxone and 800 deactivation systems annually; and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs, posted April 3, 2026. Geographically, recent activity centers on Florida, Texas, Minnesota, and Oregon (through MMCAP's multistate reach). The code shows low relevance to actual buying patterns under its current classification.